🔗 Share this article

While America undertakes sweeping revisions to its vaccine recommendations, one figure has emerged unexpectedly: Høeg, an American of Danish descent physician and public health researcher who first made her name by expressing skepticism about Covid vaccinations throughout the global health crisis and has concentrated on possible deaths following Covid immunization in her short position at the Food and Drug Administration.

Proposed Changes to Childhood Immunization Schedule

Agency leaders had intended to unveil sweeping revisions to the pediatric vaccination calendar recently, bringing the US with Denmark’s vaccine program, sources say – a significant shift that would put the US out of alignment with a large portion of the world with no evidence for public health gain. This reveal has been delayed until the next year.

Instead of the director of the vaccine center, Dr. Høeg is listed to speak at the event. She was recently named acting director of the FDA’s CDER, the fifth appointee to lead the division this calendar year.

A Shift at the Agency

Høeg's temporary position might represent a closer partnership between the drug and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the FDA – and it points to a renewed priority upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has often pushed for discontinuing some childhood shot schedules in the US to become more like Denmark's approach, a country with comprehensive healthcare and a number of inhabitants approximately the size of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccines – traditionally the domain of Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Background

The appointee has no apparent background in medication creation, oversight or management, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and CBER since spring.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a large organization. She is not an expert in industry regulation.”

Former heads of the center would “grasp laws and regulations and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that previous people who led the center have had.”

The drug center has an enormous workload at the agency, she emphasized.

“The public just focuses on the novel medication approvals, but the generic program clears thousands of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and so forth, and all of those have to be looked after,” Dr. Woodcock said. “The thing you neglect, that is the part that I always told people is going to bite you.”

Additionally, a significant administrative aspect to the position, which oversees more than 5,000 personnel. “It’s a enormous leadership role, if you execute it properly,” Woodcock added.

Response and Disputed Programs

In response to concerns about Høeg’s qualifications and whether this assignment represents more teamwork among agency officials on vaccines, a representative responded that the “concerns rely on flawed presumptions”.

“Her resume matches the duties of her role,” the spokesperson stated, citing the period Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg inherits the agency head's new expedited review system, a contentious rapid medication authorization process that apparently concerned her former heads. “How are these therapies being selected for this voucher program? Who is making the decisions?” Dr. Howard questioned. “There’s a lot of lack of transparency going on at the agency right now.”

Overall, he said, “the FDA looks to be trending towards laxer regulations of pharmaceuticals, except for vaccines.”

Established Past Work on Immunizations

Concerning immunizations, Høeg has a clearer, if troubling, track record, Howard have noted. She published a research paper using unverified volunteer-provided data to determine the incidence of myocarditis following Covid vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccinations are pose a greater threat than they are.

Among her “wish list” for the current administration encompassed altering regulations for novel immunizations and halting “optional” immunizations, she said following the vote on a audio program. At the agency, Høeg has according to sources proposed excluding young men from obtaining Covid vaccines.

“She’s an all-around true believer who begins with her beliefs and works backwards to accommodate the data in a extremely misleading, fraudulent fashion,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|